Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

progress with potential manufacturing partners for Phase 3.

In conjunction with the release of financial results for the third quarter ended September 30, 2010, Anthera will host a conference call at 5 pm Eastern Time, November 2, 2010. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190. The conference ID is 19111226. To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 19111226. The audio replay will be available until November 9, 2010. This conference call will be webcast live and archived on Anthera's website until November 2, 2011, www.anthera.com.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, varespladib, and two Phase 2 clinical programs, A-623 and A-001. Varespladib and A-001 inhibit a novel enzyme target known as sPLA2 . Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or (BAFF), which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus). For more information, please visit www.anthera.com.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements made pursuant to the safe harbor pr
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Md. , May 4, 2015   Synthetic ... pathogen-specific therapeutics focused on protecting the microbiome, as well ... has been appointed Chief Financial Officer, Treasurer and ... Evan Ballantyne who will be leaving the Company ... Shallcross brings to Synthetic Biologics operational, financial and international ...
(Date:5/4/2015)... and COLUMBIA, Maryland , May ... SHP, NASDAQ: SHPG ) and the Foundation Fighting ... research for a novel treatment for autosomal dominant retinitis ... occurs in late childhood or adolescence and is followed ... no currently approved treatment options for adRP. ...
(Date:5/4/2015)... , le 4 mai 2015  Lors du ... /Allemagne (hall 5, stand 5510), North Star Imaging ... système à rayons X spécialement conçu pour la ... sur les rayons X, la CXMM 50, a ... système de métrologie destiné à offrir à l,utilisateur ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Shire and Foundation Fighting Blindness Announce New Research Agreement 2Shire and Foundation Fighting Blindness Announce New Research Agreement 3NSI sera présente lors du salon Control 2015, du 5 au 8 mai à Stuttgart, en Allemagne : axer la GMAO vers une nouvelle dimension 2
... BOSTON, May 1, 2012 /PRNewswire-iReach/ -- ... healthcare Information Technology (IT) news and intelligence websites, ... in March.  The company also launched its first website, ... resource for electronic health record (EHR) news, intelligence, ...
... Calif., May 1, 2012  Ultragenyx Pharmaceutical Inc., a ... and ultra-rare genetic disorders, today announced results from ... in patients with hereditary inclusion body myopathy (HIBM) ... extended release profile on absorption after oral administration.  ...
Cached Medicine Technology:Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com 2Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 2Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease 3
(Date:5/4/2015)... 04, 2015 World T.E.A.M. Sports’ best-attended ... ride in the last decade arrived in this historic ... in two days from the Pentagon in Arlington, Virginia. ... registered disabled and able-bodied participants work together to successfully ... and honors the commitment and sacrifices by military veterans ...
(Date:5/4/2015)... 04, 2015 “ Food Cost Calculator ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... owners to manage and efficiently calculate food costs. , The ... In fact, the industry has an estimated 1.8 trillion dollar ...
(Date:5/4/2015)... 04, 2015 Peacock Alley knows ... He said, “My mother was the most beautiful woman I ... in lovely, feminine prints and textures to remind ... further than the Eloise Robe to get you there. The ... cap sleeve and tapered waist. It is available in small/medium ...
(Date:5/4/2015)... Sara Soulati, CEO of Global Cardio ... Los Angeles associated with the field of Enhanced External ... Sara Soulati Health For Life Program (SSHFLP). , The ... modification and disease prevention program. A provisional patent ... Patents and Trademarks Office and is now under review ...
(Date:5/3/2015)... May 03, 2015 Women’s Excellence ... Facebook page. , Their Facebook page consists ... services the Practice has, it’s multiple locations, Providers and ... Excellence has a very strong social media presence, with ... You Tube. , Women’s Excellence is the most ...
Breaking Medicine News(10 mins):Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 2Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 3Health News:Gettysburg Welcomes Arriving Face of America Riders with Gala Celebration 4Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... TV/Channel 7 and The,Detroit Department of Health and Wellness ... "boost" at the 31st annual "HEALTHY LIVING,FOR KIDS" program. ... 24,2008 from 10 a.m. to 5 p.m. at the ... inception in 1977, "Healthy Living for Kids",has provided free ...
... -- Tianyin,Pharmaceutical, Co., Inc. (OTC Bulletin Board: TYNP, ... medicine ("TCM") based in,Chengdu, China, today announced that ... OTC BB: TYNPE due to the electronic eligibility,system ... and the Company expects the,stock symbol to trade ...
... Fourteen physicians who have been,part of Commonwealth Medical ... and service they provide to their patients by joining ... and we are delighted they,have decided to join our ... officer. "We look forward to working with,them to support ...
... Aug. 20 Governor Edward,G. Rendell today said ... and a broken healthcare system, underscoring the need,to ... more,affordable for working adults., Nearly 900 guests ... & Industry Day Luncheon at Ag Progress Days, ...
... traitors, good cells gone bad. They evade the body,s defense ... , But researchers at the University of North Carolina at ... way to blow their cover. , Moo J. Cho, Ph.D., ... system that would embed bacterial elements in a cancer tumor ...
... found that infusions of a particular bone marrow stem ... in a mouse model. In their report published ... from the MGH Center for Engineering in Medicine report ... immune system activities, allowed the regeneration of the gastrointestinal ...
Cached Medicine News:Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction 2Health News:Commonwealth Medical Group Physicians to Join Aurora Health Care 2Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2Health News:UNC researcher aims to 'unmask' cancer cells to trigger body's immune system 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 2Health News:Bone marrow stem cells may help control inflammatory bowel disease 3
... bed side and near patient testing is ... growth has posed unique problems for hospitals ... quality responsibility to decentralized areas focused on ... the problem is the reality of controlling ...
... The GenoSensor System includes genomic ... software, and reagents. By utilizing ... (CGH) technology for multi-target assessment, ... analyze multiple genomic targets in ...
... The CELL-DYN 3700 combines optical light ... Polarized Scatter Separation (MAPSS) to fully ... to improve performance and productivity in ... the revolutionary concept of complementary technologies ...
... Data Networking is hospital bedside glucose ... networking. In seconds, point of care ... from nursing stations throughout the hospital ... available to laboratory staff and the ...
Medicine Products: